Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...
Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per ...
PFE was last seen up 3.7% at $26.18, chipping away at its 12.9% year-to-date deficit. A floor at $25 contained the equity's most recent pullback, while above the 40-day moving average is getting ...
TipRanks on MSN
Pfizer resumed with a Neutral at Citi
Citi resumed coverage of Pfizer (PFE) with a Neutral rating and $26 price target The firm has a balanced view on the shares. The company’s ...
Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...
Pfizer Inc. remains materially undervalued despite recent volatility, with its recovery momentum challenged by the ongoing Metsera bidding war. PFE's more stable guidance and robust pipeline offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback